Pyridoxamine
A natural form of vitamin B6 that blocks advanced glycation end-product formation in the laboratory. It was developed as a kidney drug, and the clinical trials did not meet their goals.
Evidence last reviewed: August 2026
What the science says
- Diabetic kidney disease Limited evidence
A randomised placebo-controlled trial of pyridoxamine dihydrochloride in 317 patients with type 2 diabetic nephropathy failed its primary endpoint of change in serum creatinine, with a signal only in a post-hoc subgroup with lower baseline creatinine. A follow-up phase 3 study was terminated as a pilot without demonstrating benefit.
- Vitamin B derivatives for kidney disease generally Limited evidence
A Cochrane review of vitamin B and its derivatives for diabetic kidney disease found insufficient evidence of benefit on clinically important outcomes, with concerns about harm in some B-vitamin trials.
- Anti-glycation effects Limited evidence
Pyridoxamine's ability to trap reactive carbonyls and inhibit advanced glycation end-product formation is well demonstrated in vitro and in animal models. No human study has shown that this translates into slower ageing or better long-term health outcomes.
Dosage & safety
Scientific references
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Longevity & antioxidants
- Beta-Carotene Limited evidence
- Vitamin E Limited evidence
- Astaxanthin Limited evidence
- Chaga Mushroom Limited evidence
- Olive Fruit Extract (Hydroxytyrosol) Limited evidence
- PQQ Limited evidence